Mantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki-67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression-based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61%), standard (27%) or high (12%) risk groups with significantly different outcomes. We confirm here in our prospective clinical trial cohort of MCL patients, that the MCL35 assay is strongly prognostic, providing additional information to the Ki-67 index and the MIPI. Thus, this robust assay may assist in making treatment decisions or in devising risk-adapted prospective clinical trials in the future.
Mantle cell lymphoma (MCL) is a rare and incurable B cell Non-Hodgkin lymphoma characterized by the t(11;14)(q13; q32) translocation, which leads to cyclin D1 overexpression (Raffeld & Jaffe, 1991; Williams & Swerdlow, 1994) and cell cycle deregulation (Jares et al, 2012) . The course of the disease varies, with most patients requiring immediate, aggressive treatment initiation, while a few others need no treatment for several years (Abrisqueta et al, 2017) . As MCL is still incurable, it becomes important to identify patients who will benefit from specific therapies compared to patients, especially of older age, who may benefit from a "watch and wait" strategy (Vose, 2017) . At present, generally accepted risk-adapted management and treatment strategies for MCL patients are lacking (Zelenetz et al, 2014; Dreyling et al, 2017; Arora & Portell, 2018; Kluin-Nelemans & Doorduijn, 2018; McCulloch & Rule, 2018) . However, in the last few years different approaches and prognostic tools have evolved in order to risk-stratify MCL patients. Specifically, the Mantle Cell Lymphoma International Prognostic Index (MIPI), which is based on independent prognostic factors including age, Eastern Cooperative Oncology Group (ECOG) performance status, lactate dehydrogenase (LDH) level and leucocyte count (Hoster et al, , 2014 , was established as the first prognostic index for MCL patients, opening the door for risk-adapted treatment decisions. On the other hand, Ki-67 staining by immunohistochemistry identifies proliferating cells and this index has demonstrated strong prognostic relevance in MCL both alone (Tiemann et al, 2005; Katzenberger et al, 2006; Determann et al, 2008) and in combination with the MIPI . However, Ki-67 staining and interpretation is subject to considerable interlaboratory and interobserver variability (de Jong et al, 2007) . Assays using gene expression profiling identified a proliferation signature with strong prognostic relevance in MCL more than a decade ago. It was suggested that the gene expression-based measurement of the proliferation signature might serve as an 'integrator' of the underlying genetic lesions of the MCL cells for predicting survival (Rosenwald et al, 2003) . However, this method demanded fresh frozen tumour material and specific microarray platforms and did not advance to clinical use. Nonetheless, based on the information of this original proliferation signature and the use of the NanoString technology platform, a new gene expression assay (MCL35) was developed that is applicable to formalin-fixed, paraffinembedded (FFPE) tissues. The MCL35 score has been shown to be prognostic for the overall survival (OS) of MCL patients independently from clinical prognostic factors (Scott et al, 2017a) , and cut-offs have been derived to define three prognostic groups (low, standard and high risk) with significantly different survival times. This robust and highly reproducible assay was validated on a population-based, homogenously treated MCL patient cohort and showed a stronger prognostic power than the Ki-67 index.
In this study, we validate the MCL35 gene expression assay in diagnostic material from patients treated in the prospective MCL Younger (NCT00209222) and MCL Elderly (NCT00209209) trials, registered with ClinicalTrials.gov, of the European MCL Network that established treatment strategies recommended by current clinical guidelines (KluinNelemans et al, 2012; Hermine et al, 2016) .
Methods

Patient and probe selection
Among the patients with a confirmed diagnosis of MCL recruited by the German Low-Grade Lymphoma Study Group (GLSG) to the European MCL Younger or MCL Elderly trials, those with available pre-treatment FFPE material showing more than 60% tumour cell content were considered eligible for inclusion into the study. The MCL35 gene expression assay was performed and 169 tumour specimens passed the quality control. Ten percent of performed assays failed. Only MCL35 values generated on lymph node (LN) samples were used for the core analysis, leaving 127 biopsies with MCL35 data (Table I ). An additional analysis on 42 non-nodal tissue samples from patients also enrolled in the MCL Younger or MCL Elderly trials was performed, including tonsils, soft tissue, gastrointestinal biopsies and other samples. The selection of patients from all MCL Younger and MCL Elderly trial patients is illustrated in Fig 1. No relevant differences were observed for baseline characteristics, treatment and outcome between the GLSG patients with MCL35 score versus those without MCL35 score on LN samples (Table I, Figure S1 ). Gene expression profiling RNA was extracted from 10 lm sections of FFPE biopsies with the QIAGEN AllPrep DNA/RNA FFPE Kit (QIAGEN, Hilden Germany) following deparaffinization according to the manufacturer's instructions. Gene expression profiling was performed on the NanoString platform (NanoString Technologies, Seattle, WA, USA) using 200 ng of RNA with a first generation nCounter â analyser, as described previously (Scott et al, 2017a) .
Immunohistochemistry for Ki-67
Immunohistochemical staining for Ki-67 was performed according to standard protocols with the Ki-67 antibody, clone MIB-1 (M7240) (Dako/Agilent, Santa Clara, CA, USA) and the Ki-67 index was assessed by counting 200 lymphoma cells in representative tumour areas, following published guidelines (Klapper et al, 2009) . The results for the prognostic value of the Ki-67 index in the combined MCL Younger and Elderly cohort have been published previously .
Definition of variables and statistical analysis
Outcome variables include OS (measured from trial registration to death from any cause) and failure-free survival (FFS, from treatment start to failure to achieve a remission during induction treatment, progression, or death from any cause; data cut-off 7 November 2017). The cut-offs for risk group assignment according to MCL35 were -143 and -28, with right-closed intervals. The association of the MCL35 score and clinical and histopathological characteristics was investigated using Spearman's rank correlation coefficient (q). The prognostic value of the MCL35 score was analysed using Cox regression, adjusting for MIPI score and Ki-67 index, and Kaplan-Meierestimation with log-rank tests. For primary analysis, data from the trials and treatment groups were pooled in order to maximize statistical power. As sensitivity analyses, subgroup analyses including statistical testing of heterogeneity between subgroups using Cox regression were performed for the two trials and for treatment groups in the MCL Younger trial. For the primary question of overall survival according to MCL35 risk groups, a P-value smaller than 0Á05 was considered statistically significant. Any other P-value was interpreted as measure for the strength of evidence against the respective null hypothesis.
Results
The MCL35 score is strongly associated with the Ki-67 index and MCL cytology
The median value for the MCL35 score on 127 LN samples was À177 (range, À345 to 176). According to the MCL35 score, 61%, 27% and 12% of patients were classified as low, standard and high risk, respectively. The MCL35 score was not associated with age (q = 0Á10, P = 0Á26) and ECOG performance status (q = 0Á05, P = 0Á60) of MCL patients but showed a weak correlation with LDH level (q = 0Á28, P = 0Á0015), white blood cell (WBC) count (q = 0Á19, P = 0Á034) and the MIPI score (q = 0Á23, P = 0Á011). In contrast, there was a strong correlation of the MCL35 score with the Ki-67 index (n = 101; q = 0Á67, P <0Á0001) and No clinical followup is available from 15 of the 171 MCL patients with MCL35 data, of whom 2 were lost to follow-up. In the remaining patients, documentation has to be completed as these were registered to the MCL Younger trial after stop of randomization. There were 66 failurefree survival (FFS) events among the 113 patients with data on MCL35 on LN and FFS. Among the 127 MCL patients with data on MCL35 on LN we have observed 52 overall survival events so far. GLSG, German LowGrade Lymphoma Study Group; HOVON, Haemato Oncology Foundation for Adults in the Netherlands; MALT, mucosa associated lymphoid tissue; FL, follicular lymphoma; LN, lymph nodes; MCL, mantle cell lymphoma.
MCL cytology (blastic versus non-blastic, n = 89; q = 0Á40, P = 0Á0001) (Fig 2) .
The MCL35 score has strong prognostic relevance
In our cohort, MIPI score and Ki-67 index were independently prognostic for OS and FFS (Table SI) . The MCL35 score showed a strong prognostic relevance for OS, without (hazard ratio [HR] per increment of 100, 1Á87, 95% confidence interval [CI] 1Á45-2Á42, P < 0Á0001) or with adjustment for the MIPI score (HR 1Á73, 95% CI 1Á32-2Á26, P = 0Á0001). Likewise, in context with the numerical Ki-67 index, without (HR 1Á77, 95% CI 0Á99-3Á15) or with (HR 1Á73, 95% CI, 0Á97-3Á09) adjustment for the MIPI score, the MCL35 score added prognostic value to the other indices. However, when adjusting for the binary Ki-67 index (high: ≥30% versus low: <30%), with or without MIPI score consideration, the Ki-67 index had a stronger prognostic value for OS (Table II) . Similar results were observed for FFS (Table II) . The MCL35 risk groups show distinct differences in OS and FFS
The three risk groups according to the MCL35 score showed substantial differences in OS, without (standard versus low, HR: 2Á39, 95% CI 1Á30-4Á41, high versus standard 3Á41, 1Á52-7Á64) and with adjustment for the MIPI score (standard versus low, HR: 2Á27, 95% CI 1Á23-4Á20, high versus standard 2Á76, 1Á21-6Á31; Fig 3A, Table SII) . Furthermore, the differences between the three risk groups were similarly observed in both the MCL Younger and MCL Elderly trials (Fig 3C, D, P = 0Á78 for the heterogeneity test). Moreover, among patients with a high Ki-67 index (≥30%), the MCL35 risk groups further separated patients with considerable differences in OS (Fig 3E) . However, the MCL35 assay did not clearly stratify the risk groups in patients with a Ki-67 <30% (data not shown For the numerical MCL35 score, hazard ratios were calculated per increment of 100 in accordance with its wide numerical range. CL, confidence limit; MIPI, mantle cell lymphoma International Prognostic Index. and in both treatment groups differences in OS between the MCL35 risk groups became evident (Fig 3F and G) . In MCL Younger, among patients treated with R-CHOP/R-DHAP, the MCL35 standard risk group tended to have outcome more similar to the low risk group, in contrast to the R-CHOP treated group, where MCL35 standard risk patients had inferior outcome (P = 0Á053 for the heterogeneity test). Additionally, in an adjusted analysis for the MIPI or the Ki-67 index as numerical score with or without MIPI in the full analysis cohort, the MCL35 risk groups had a stronger prognostic value for OS. However, when adjusting for the binary Ki-67 index (≥ or <30%), with or without MIPI, the MCL35 high versus standard groups appeared almost as strong as the Ki-67 index, while standard versus low groups did not appear prognostic (Table SII) . For the most part, similar results were obtained in the analysis of FFS. Here the differences between the MCL35 standard and low groups were smaller than those between the high and standard groups ( Fig 3B and Table SII ).
(B) (A)
The MCL35 score in non-nodal MCL specimens
In addition, we applied the MCL35 assay to non-nodal MCL tissues, including tonsils (n = 16), gastrointestinal biopsies (n = 11), soft tissue specimens (n = 10) and other materials (n = 5). The median value for the MCL35 score assessed on 42 non-nodal MCL specimens was À136 (range À324 to 169). Forty-three percent, 45% and 12% of MCL patients were assigned to the MCL35 low, standard and high risk groups, respectively. Also, in non-nodal tissue samples, the MCL35 score was prognostic for OS (HR for an increment of 100, 1Á99, 95% CI, 1Á20-3Á31, Table SIII ) that translated into a trend towards different survival according to the MCL35 risk groups (Fig 3H) .
Discussion
Our study confirms that the NanoString platform-based MCL35 assay is a reliable prognostic biomarker in MCL patients for identifying subgroups with different outcomes via a proliferation signature-based score. Specifically, we here validate its previously described prognostic power on two prospective clinical trial cohorts, namely in the MCL Younger and MCL Elderly trials of the European MCL Network. As a continuous score, the MCL35 clearly separated three patient groups with low, standard and high risk. It is significantly correlated with the routinely used Ki-67 index of the tumour cells as well as with MCL cytology (classic versus blastic/pleomorphic types). Remarkably the MCL35 assay was also able to identify the three risk groups within the patient subgroup with a high Ki-67 index (≥30%). Additionally, our study may provide first hints that the MCL35 standard risk group may benefit from a more intensified treatment approach. In the MCL Younger trial, the OS curve of the standard risk group converged with that of the low risk group when patients were treated with R-CHOP/R-DHAP, while this did not appear to be the case when patients were treated with R-CHOP alone. Although patient numbers were relatively small in this subgroup analysis, similar findings were observed in a MCL patient cohort of 74 Norwegian patients treated with a similar protocol within the Nordic Lymphoma Study Group Kolstad et al, 2014) . Thus, although all MCL35 risk groups in the Nordic study had an improved survival compared to the original publication from British Columbia (Scott et al, 2017a) , the standard risk group seems to benefit from intensified treatment more than the other two groups. Results from applying the MCL35 assay to biopsies from patients enrolled in the Cancer and Leukaemia Group B 50403 (Alliance) trial, comparing intensive regimens in young patients, were also consistent (Scott et al, 2017b) . Of note, the proportion of risk groups in our study differs significantly from the original publication (Scott et al, 2017a) . One possible explanation could be the fact that the option for an initial watch and wait approach in MCL with measurable disease was implemented earlier in British Columbia as compared to Europe. Therefore, the inclusion criteria of MCL patients in the original publication (treatment within 3 months following the diagnostic biopsy) may have led to a decreased number of patients in the low risk group (Abrisqueta et al, 2017) .
Recently, the prognostic value of TP53 expression was described in patient samples from the MCL Younger and Elderly trials (Aukema et al, 2018) . In combination with our data, we found an expected correlation between MCL risk groups and TP53 expression: the higher the MCL risk group, the higher the percentage of patients with TP53 expression >50% (data not shown).
While the MCL35 assay appears to be a reliable and robust gene expression-based assay with a strong prognostic value for the survival of MCL patients using routinely available FFPE biopsies, there are also shortcomings. So far, the MCL35 assay has been established only for biopsies from involved lymph nodes with a high tumour load (≥60%) (Scott et al, 2017a) , precluding the analysis of tumour samples with scarce MCL infiltrates, e.g. in the gastrointestinal tract or in nodal MCL cases with a mantle zone infiltration pattern. However, judging from our limited experience on 42 samples, the assay may have value in MCL infiltrates in other tissues (tonsil, soft tissue etc.), if the tumour cell content is sufficient (≥60%). This assay is not aimed for MCL patients that show a leukaemic, non-nodal disease, but a new assay to classify patients with leukaemic MCL into risk groups was very recently published (Clot et al, 2018) . In addition, the MCL35 assay failed technically, partly due to poor fixation of the FFPE sample but in the majority of cases for unknown reasons in approximately 10% of these archival MCL specimens that otherwise fulfilled the inclusion criteria. No correlation between failed samples and RNA quality, sample material (LN or other tissue) or sample age was detected.
Given the fact, however, that the widely used Ki-67 index is prone to significant interlaboratory and interobserver variability, the gene expression-based measurement of proliferation using the MCL35 assay may be of value to support treatment decisions and risk-adapted strategies in future clinical trials.
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